AEON רווח נקי למניה ב-12 החודשים האחרונים aeonbiopharma.com

AEON Biopharma (AEON) has focused on independently penetrating the B2B aesthetics market, which triggered a sharp surge in the trailing twelve-month earnings per share trend. This growth is supported by the successful trials of ABP-450 and patent protection. The drug's unique binder-free composition enables the company to maintain pricing power. The value of -3.77 reflects the metric's baseline, confirming the business's capitalization potential.

This metric reflects the portion of net income attributable to a single common share over a rolling year. The metric allows for an assessment of real capital generation efficiency by excluding the impact of the total issuance volume. By analyzing the 12-month net income per share trend, an investor can identify hidden anomalies in accounting policy. This is critical for AEON Biopharma (AEON), as production outsourcing minimizes capital expenditures but increases the dependence of profits on vendor contract terms.